Physician profile
Bruce S Kahn
NPI 1396704078
$78,662.00
in general payments reported to CMS, 2019-2025
35 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $4,381 · 2021: $8,527 · 2022: $838 · 2023: $7,065 · 2024: $11K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Consulting Fee: $10K · Education: $4,099 · Food and Beverage: $1,921 · Travel and Lodging: $1,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,667.50 |
| Consulting Fee | $10,250.00 |
| Education | $4,099.00 |
| Food and Beverage | $1,920.52 |
| Travel and Lodging | $1,852.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27,727.64 | 2019-2023 | |
| Astellas Pharma US INC | $15,798.95 | 2021-2025 | Veozah |
| Virtual Incision Corporation | $9,496.09 | 2024-2025 | Mira |
| Caldera Medical, INC | $7,097.29 | 2019-2024 | Desara |
| Boston Scientific Corporation | $6,508.37 | 2019 | |
| Intuitive Surgical, INC. | $5,812.44 | 2019-2025 | |
| Heron Therapeutics, INC. | $3,075.48 | 2019 | |
| Ibsa Pharma INC. | $675.00 | 2021 | |
| Asensus Surgical, INC. | $600.00 | 2022 | |
| Valencia Technologies Corporation | $496.34 | 2023 | Ecoin Device Kit |
| Baxter Healthcare | $292.83 | 2022-2023 | Perclot |
| Myovant Sciences INC. | $170.41 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $123.35 | 2023-2024 | Myfembree, Gemtesa |
| Becton, Dickinson and Company | $106.12 | 2023-2024 | Arista Ah Flexitip, Bd Onclarity |
| Coopersurgical, INC. | $90.01 | 2019-2024 | Paragard T 380a, Paragard T 380a |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80.70 | 2019-2023 | |
| Meditrina | $57.76 | 2025 | |
| Allergan, INC. | $41.45 | 2019-2020 | |
| Biogen, INC. | $41.20 | 2025 | Zurzuvae |
| Evofem Biosciences, INC. | $40.15 | 2021-2024 | |
| Hologic Sales and Service, LLC | $35.92 | 2024-2025 | Fetal Fibronectin Enzyme Immunoassay, Acessa Provu System, Novasure |
| Olympus America INC. | $35.81 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $34.67 | 2025 | |
| Kedrion Biopharma INC. | $28.72 | 2019 | |
| Merck Sharp & Dohme LLC | $26.75 | 2019 | |
| Duchesnay USA Incorporated | $22.17 | 2019 | |
| Mayne Pharma Commercial LLC | $21.73 | 2025 | |
| Viiv Healthcare Company | $21.07 | 2024 | Apretude |
| Millicent US INC | $20.98 | 2025 | Femlyv |
| Exeltis, USA INC. | $20.70 | 2019 | |
| Dysis Medical, INC. | $18.25 | 2019 | |
| Aspira Women'S Health INC | $18.04 | 2024 | Ova1 |
| Minerva Surgical, INC | $13.69 | 2019 | |
| Therapeuticsmd, INC. | $11.92 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.